Find the Right Backbone for your Application
Aldevron now offers pALD-CV42 [T7] and pALD-CV42 [T7-PolyA]. These cloning backbones contain the T7 promoter region for RNA production, with an option for encoded poly(A) available in one construct.
Aldevron's cloning vectors are available as free samples. If you are interested, please fill out the Request Sample form.
Interested in rAAV Manufacturing? Check out rAAV specific ITR cloning vectors.
pALD-CV42 Quality Control Specifications
Appearance | Clear and Colorless |
Buffer | TE |
Concentration | 1.0mg/mL +/- 10% |
DNA Homogeneity | Predominately Supercoiled |
Endotoxin | ≤ 100 EU/mg |
Identity | Confirmed Against DNA Ladder |
Plasmid Identity | Identical to Reference Sequence |
ABS 260/280 Ratio Purity | 1.80 – 2.00 |
Residual Host Genomic DNA | ≤ 5% |
Residual Host RNA | Not Visible at 200 ng Load |
Restriction Digest | Matches Expected Restriction Pattern |
pALD-CV77, pALD-CV42 [T7] and pALD-CV42 [T7-PolyA] Quality Control Specifications
Appearance | Clear and Colorless |
Buffer | TE |
Concentration | 1.0mg/mL +/- 10% |
DNA Homogeneity | ≥ 80% Supercoiled |
Endotoxin | ≤ 100 EU/mg |
Identity | Size Confirmed Versus Supercoiled Marker |
Plasmid Identity | Identical to Reference Sequence |
ABS 260/280 Ratio Purity | 1.80 – 2.00 |
Residual Host Genomic DNA | ≤ 5% |
Residual Host RNA | Not Visible at 200 ng Load |
Restriction Digest | Matches Expected Restriction Pattern |
Commonly Asked Questions
Q: What are the main key features of this construct set?
A: Aldevron offers this construct set royalty free for research through commercial production. Complimentary samples are available for cloning and testing purposes.
Q: Are there any clinical trial references available using this construct?
A: Yes. The pALD-CV77 cloning backbone is based on the pWRG7077 sequence which has been used in a number of clinical trials; please see references below (individual results may vary).
The pALD-CV42 cloning backbone is currently used in research applications.
NCBI:
Clinicaltrials.gov:
Combination HTNV and PUUV DNA Vaccine